Vandetanib
Vandetanib is a pharmaceutical drug with 57 clinical trials. Currently 3 active trials ongoing. Historical success rate of 71.7%.
Success Metrics
Based on 33 completed trials
Phase Distribution
Phase Distribution
22
Early Stage
27
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
66.0%
33 of 50 finished
34.0%
17 ended early
3
trials recruiting
57
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Clinical Trials (57)
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Vandetanib in Advanced NSCLC With RET Rearrangement
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 57